Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate Cancer /von T. M. Wheeler, B. Zhao, G. Sonpavde, J. D. McMannis, Y. Bai, N. Lapteva, M. Seethammagari, J. M. Levitt, D. M. Spencer, K. M. Slawin; Department of Pathology, Baylor College of Medicine, Houston, TX; University of Texas Health Science Center at Houston, Houston, TX; Texas Oncology, Baylor College of Medicine, Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Memorial Hermann Hospital-Texas Medical Center, Houston, TX; Baylor College of Medicine, Houston, TX; Vanguard Urologic Institute, Houston, TXCapacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)
/in Hyperthermia, International Publications, Prostate Cancer /von Mahdavi SR, Janati Esfahani A, Khoei S, Bakhshandeh M, Rajabi APotentiating prostate cancer immunotherapy with oncolytic viruses
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von Lee P, Gujar SMyeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
/in Dendritic Cells, International Publications, Prostate Cancer /von Harm Westdorp, Inge M. van Oort, Jeroen H.A. Creemers, Gerty Schreibelt, Niven Mehra, Anna L. de Goede, Christina Hulsbergen-Van De Kaa, Carl G. Figdor, Alfred Witjes, Erik H.J.G. Aarntzen, Roel D.M. Mus, Martin Gotthardt, Jelle O. Barentsz, Jolanda De Vries, Winald R. Gerritsen; Radboud University Nijmegen Medical Center, Nijmegen, NL; Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; Radboud Institute for Molecular Life Sciences, Nijmegen, NetherlandsGenetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von Raghunath S, Pudupakam RS, Allen A, Biswas M, Sriranganathan NProstate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von Alberti CCurrent status of clinical trials assessing oncolytic virus therapy for urological cancers
/in Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von Taguchi S, Fukuhara H, Homma Y, Todo TA comprehensive review of immunotherapies in prostate cancer
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von Maia MC, Hansen ARDendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
/in Dendritic Cells, International Publications, Prostate Cancer /von Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, Svane IM
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma.
- Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.
- Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).